- Savel to oversee manufacturing and quality operations -
FREMONT, Calif., March 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(Nasdaq: PDLI) today announced that Bob Savel will join the company as
senior vice president of technical operations, overseeing all manufacturing
and quality functions at both the company's Minnesota and California sites.
Savel will report to PDL's chief executive officer, Mark McDade.
"We're pleased to welcome Bob to PDL at this turning point in the
company's evolution," said Mark McDade, chief executive officer, PDL
BioPharma. "We're on the cusp of advancing several of our products into
later-stage clinical trials, our early stage pipeline is progressing and
our research labs are well on pace to meet our goal of identifying a new
clinical antibody candidate each year. Bob will ensure that our quality and
manufacturing standards remain at the highest level for all our commercial
and clinical programs, while working to optimize our efficiency and
processes in these key areas."
Prior to joining PDL, Savel served as Johnson & Johnson's (J&J) vice
president of quality and compliance for the North American Region for
Pharmaceuticals, where he led a large quality assurance and lab
organization at multiple sites that manufactured biologics,
pharmaceuticals, transdermals, cytotoxic agents and drug/device
combinations. During his seven-year tenure at J&J, he served in many
positions of increasing responsibility within manufacturing and quality.
Before J&J, Savel worked as a principal management consultant at Price
Waterhouse Coopers (PWC). While at PWC, he led consultant teams that drove
improvements in performance, culture and organizational structure for
pharmaceutical companies, with a particular focus on manufacturing
operations. He also held manufacturing positions at Ingersoll-Rand
Corporation and Virginia Power. Savel received his Bachelor of Science
degree in mechanical engineering from Virginia Tech.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of products in the
United States and Canada. A pioneer of antibody humanization technology,
PDL promotes this technology through licensing agreements and clinical
development of its own diverse pipeline of investigational compounds. PDL's
research platform centers on the discovery and development of antibodies to
treat cancer and autoimmune diseases. For more information, please visit
http://www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com/
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, or ami.knoefler@pdl.com, or Jean
Suzuki, Investor Relations, +1-510-574-1550, or
jean.suzuki@pdl.com, both of PDL BioPharma, Inc.
|
